Defunct Company
Total Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
639
NCT03993626
A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
Phase: Phase 1/2
Role: Lead Sponsor
Start: May 22, 2018
Completion: Jun 15, 2020
NCT03873025
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Role: Collaborator
Start: Oct 31, 2019
Completion: Apr 30, 2025
NCT04448106
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
Phase: Phase 2
Start: Sep 25, 2023
Completion: Aug 15, 2026
NCT04428801
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
Start: Sep 30, 2023
Completion: Sep 30, 2026
NCT04170426
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
Start: Dec 31, 2023
Completion: Dec 31, 2026
NCT05017298
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
Start: Nov 1, 2024
Completion: Nov 15, 2026